Please note:
- I'm just sharing my view. its not a recommendation for buying or selling.
- penny stocks moves most of the times are " pump n dump". don't chase them, and you must have an exit plan.
if next 15m candle closes above 3.22 will be bullish on it
Now or never, This is a key level. Gap will fill if trendline rejects. need a close above 3.22
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma
Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE)
$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included
finance.yahoo.com
Can-Fite BioPharma Ltd. engages in the development of drugs for cancer and inflammatory diseases. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
CAN FITE BIOPHARMA (NYSE:CANF) proliferated 11.24% since last week. The company, on June 30 announced its final data analysis of the NASH study, which is in Phase-II. The company announced that it observed positive data, where there was sustained reduction and highly efficient too, in the volume of fat liver, across the study duration.
The company is conducting...
A succesful breakout of $2.50 could lead to $3.75
Not investment advice. Trade safely.
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharmaceutical company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it is submitting its annual Drug Safety Update Reports (DSUR) for both Piclidenoson and Namodenoson to the governing health regulatory agencies where its...
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. The company offers drugs for the treatment of...
CCI dipped below -100, lines up with bottom tail and bottom of the BBs, also has HEAVY volume. Weekly chart. Happy trading! Please leave feedback / criticism in comments. Thanks!
Is she can fight? fight that Liver cancer?
Technical, Not yet there for good signs...
1.17 .....1.23-1.24 (MA200)
I'm in and taking that risks
Good-luck to holders and CANF
